SARS-CoV-2 (COVID-19) Spike S1 Antibody Cat. No.: 9083

Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in Human Lung Tissue from the COVID-19 Patient (Sun et al., 2020)
Detection of SARS-CoV-2 nucleocapsid protein by anti-SARS-COV-2 nucleocapsid antibodies (9099, 0.02 μg/mL, A,B) or SARS-CoV-2 Spike S1 antibodies (9083, 1 μg/mL D,E) in adjacent sections of autopsy lung tissue from COVID-19 deceased patient. Negative control staining on autopsy lung tissue from patient who died from non-COVID-19 pneumonia is shown for Nucleocapsid protein (C) or Spike protein (F). Negative control using normal rabbit immunoglobulin on COVID-19 autopsy tissue is presented (G). DAB chromogen and hematoxylin counterstain are used. Scale bars: 50μM in A, C, D, F, G; 20μM in B and E. See high quality image.

Figure 2 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 spike protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung. See high quality image.

Figure 3 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 spike protein was observed in macrophage of COVID-19 patient lung. See high quality image.

Figure 4 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in Human Lung Tissue from the COVID-19 Patient
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Hallgeir Rui, MCW) (Picture shown in 40X magnification) See high quality image.

Figure 5 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in Human Lung Tissue from the COVID-19 Patient
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Hallgeir Rui, MCW) (Picture shown in 40X magnification) See high quality image.

Figure 6 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in Human Lung Tissue from the COVID-19 Patient
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Hallgeir Rui, MCW) (Picture shown in 40X magnification) See high quality image.

Figure 7 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in Human Lung Tissue from the COVID-19 Patient
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Hallgeir Rui, MCW) (Picture shown in 40X magnification) See high quality image.

Figure 8 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in Human Lung Tissue from the COVID-19 Patient
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Hallgeir Rui, MCW) (Picture shown in 20X magnification) See high quality image.

Figure 9 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Spike S1 in Human Lung Tissue from the COVID-19 Patient
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Spike S1 antibody (9083, 1 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. (Courtesy of Hallgeir Rui, MCW) (Picture shown in 20X magnification) See high quality image.

Figure 10 Overexpression Validation in Spike Transfected 293 Cells
Loading: 10 μg per lane of 293 cell lysate. Antibodies: SARS-CoV-2 (COVID-19) Spike S1, 9083 (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: WT 293 cells and Lane 2: SARS-CoV-2 Spike overexpressed 293 cells See high quality image.

Figure 11 Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Spike S1 in 293 Transfected Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed Spike transfected 293 cells labeling SARS-CoV-2 (COVID-19) Spike S1 with 9083 at 5 mg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). See high quality image.

Figure 12 ELISA Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein
Antibodies: SARS-CoV-2 (COVID-19) Spike S1 antibody, 9083. A direct ELISA was performed using SARS-CoV-2 (COVID-19) Spike S1 recombinant protein (97-087) as coating antigen and the anti-SARS-CoV-2 (COVID-19) Spike S1 antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 8 ng/mL to 1000 ng/mL. See high quality image.

Figure 13 Western Blot Validation with SARS-CoV-2 (COVID-19) Spike Recombinant Protein
Loading: 50 ng per lane of SARS-CoV-2 (COVID-19) Spike S1 recombinant protein (97-087). Antibodies: SARS-CoV-2 (COVID-19) Spike 1, 9083, 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: 1 μg/mL and Lane 2: 2 μg/mL See high quality image.